Background {#Sec1}
==========

Studies show that over 50% of elderly patients take five or more drugs, both prescription and over-the-counter \[[@CR1]\]. A cross-sectional study in Germany revealed further that 62% of people aged 65 or older suffer from multimorbidity \[[@CR2]\]. This combination of multimorbidity and polypharmacy leads to a higher risk for drug-drug interactions and adverse drug reactions (ADRs) \[[@CR3], [@CR4]\]. Hence, the use of drugs should be considered carefully in geriatric patients. Part of this consideration should be to avoid potentially inappropriate medications.

Drugs with anticholinergic properties are part of inappropriate medications for geriatric patients \[[@CR5], [@CR6]\]. Anticholinergic activity of multiple drugs add up to the so-called anticholinergic burden (ACB). Older patients are more prone to anticholinergic side effects than younger patients \[[@CR5], [@CR6]\]. Due to reduced metabolic capacity and slowed elimination in older patients, drugs are eliminated slower, in addition to age-related reductions in cholinergic transmissions \[[@CR5], [@CR6]\]. The permeability of the blood-brain-barrier increases which leads to a higher drug concentration in the central nervous system \[[@CR7]\]. Central nervous ADRs may especially increase the risk of falls, e.g. blurred vision, confusion, or tremors \[[@CR6]\]. More severe anticholinergic side effects are tachyarrhythmia, hallucinations, delirium, and cognitive impairment \[[@CR6]\]. Other ADRs like dry mouth, constipation, and urinary retention might reduce the quality of life \[[@CR6]\]. Several reviews indicate a higher risk for falls, cognitive decline and delirium with an increased ACB of older patients \[[@CR8]--[@CR12]\].

Despite these apparent risks it is estimated that approximately 50% of elderly people take anticholinergic medications \[[@CR13], [@CR14]\]. Qualitative studies demonstrated that very few prescribers are aware of the anticholinergic properties of drugs and of the nature of anticholinergic side effects \[[@CR15]\]. Even if they know about the negative impact of anticholinergic medications, they hesitate to deprescribe or change those drugs as they do not feel responsible or lack time, knowledge, and resources \[[@CR16]\]. In clinical practice there is rarely a registration, documentation and/or conscious reduction of the ACB \[[@CR15], [@CR17]\].

Worldwide studies identified over 100 different drugs as having anticholinergic properties \[[@CR9], [@CR10], [@CR18]--[@CR33]\]. Depending on study population, method, and setting, there are different drug lists and different scales to calculate the ACB \[[@CR18], [@CR19]\]. The variety of scales and systems complicates the implementation in practice.

Therefore, the current study aimed to develop an anticholinergic burden score specifically for the German healthcare system. This, in turn, can help German prescribers identify and reduce drugs with anticholinergic properties in geriatric patients in order to facilitate easy application in the daily clinical setting. To our knowledge a specific ACB score for Germany is not yet available.

Methods {#Sec2}
=======

To identify appropriate tools, PubMed was searched for systematic reviews on tools to quantify anticholinergic drug burden. The search terms were "review AND anticholinergic burden AND (scale OR list OR tool)" without a date limitation. The search was conducted on December 1, 2016. The search and identification process is presented in Fig. [1](#Fig1){ref-type="fig"}. Articles were excluded if they were not systematic reviews on tools to quantify anticholinergic drug burden or the language was not English. Three systematic reviews \[[@CR11], [@CR18], [@CR34]\] were included identifying 12 tools to quantify anticholinergic burden \[[@CR10], [@CR20]--[@CR26], [@CR32], [@CR33], [@CR35], [@CR36]\]. Tools were excluded because the scoring system was not comparable to the other tools \[[@CR33], [@CR36]\], the tool was outdated, \[[@CR35]\] there was an updated version published \[[@CR32]\], or the scoring was solely based on serum assays \[[@CR25]\]. Literature reviews and meta-analysis failed to show an association of serum anticholinergic activity and anticholinergic effects \[[@CR37]\], whereas there is an association shown for anticholinergic drug scores mainly based on expert opinion \[[@CR8]--[@CR12], [@CR27]\]. To avoid missing relevant tools, the excluded articles were reviewed regarding more tools as they all evaluated the association of anticholinergic drugs and negative outcomes in patients \[[@CR9], [@CR19], [@CR27], [@CR38], [@CR39]\]. These reviews identified four further tools, all ineligible for inclusion because (1) it was impossible to access the drug list despite contacting the authors \[[@CR28], [@CR31]\], (2) the scoring system was not comparable to other drug lists \[[@CR29]\], and (3) the study assessed the overall medication of patients not specific drugs \[[@CR30]\]. The included anticholinergic drug lists were summarized and reduced to drugs available in Germany \[[@CR10], [@CR20]--[@CR24], [@CR26]\]. For Boustani et al. an updated version was included \[[@CR10], [@CR40]\].Fig. 1Identification of tools

The approach to merge the identified scales was similar to the approach of Duran et al. \[[@CR18]\]. For all scales, quantitative grading scores proposed by the authors were extracted. Most lists used scores ranging from 0 to 3, one was modified according to Duran et al. so that its 0--4 scale was comparable to 0--3 scales \[[@CR18], [@CR24]\]. Topical, ophthalmic, otic and nasal drugs were excluded, while oral, parenteral, inhalative and transdermal drugs were included as these are more likely to show systemic effects \[[@CR41]\]. As these lists have only low to moderate concordance, the algorithm depicted in Fig. [2](#Fig2){ref-type="fig"} was used to get a consistent scoring.Fig. 2Algorithm for consistent scoring

Where further evaluation was needed as existing lists scored them differently or only one of the scores evaluated that specific drug., one researcher (EK) looked at the mechanism of action and the ADRs as reported in the German Summary of Product Characteristics and DRUGDEX® (expert-reviewed database for detailed drug information) to assess the anticholinergic properties of the respective drug. This assessment, the existing scores and the scoring by Duran et al. \[[@CR18]\] were discussed in a multidisciplinary team of one geriatrician and two clinical pharmacists. This discussion led to a final score. Each drug was coded according to the Anatomical, Therapeutic and Chemical (ATC) Classification from the World Health Organization. If there were discrepancies in rating within the same drug class, we reconsidered some ratings as well.

In order to tailor the ACB list to the clinical setting a retrospective evaluation of admission and discharge medication on an acute geriatric ward identified a range of further drugs. Consecutive patients for two 6-week-periods were included, which meant the admission and discharge medication of 34 patients was evaluated. The patients were prescribed a total of 235 drugs at admission and 276 drugs at discharge. All drugs thus identified that were not mentioned in the reviewed scales were evaluated for their anticholinergic properties as described above. Based on our final anticholinergic drug list, we designed a pocket-sized guideline for prescribers with information on anticholinergic drugs, anticholinergic side effects and recommendations how to assess and handle the ACB of patients on ward. The recommendation was based on the approach of Boustani et al. and is presented in Fig. [3](#Fig3){ref-type="fig"} \[[@CR10]\].Fig. 3Recommendation for prescribers on pocket-card based on Boustani et al. \[[@CR10]\]

The anticholinergic scores of all drugs used by a patient were calculated in total. If one drug scored 3 or the patient had a summated score of 3 or higher, it was recommended to switch to alternative drugs with a lesser ACB score in order to reduce the summated score to \< 3 \[[@CR10]\]. If discontinuation or switching was not possible, a dose reduction and/or monitoring for ADRs were advised. Through the upper limit of score 3, the suggested ceiling effect of the ACB is included \[[@CR19]\]. This means that at a high ACB, drug effects are assumed to reach a plateau even when the number of anticholinergic drugs further increases \[[@CR19]\].

Results {#Sec3}
=======

The summary of existing anticholinergic drug lists \[[@CR20]--[@CR24], [@CR26], [@CR40]\] resulted in a list of 692 different drugs with 548 available in Germany (for excluded, international drugs see Additional file [1](#MOESM1){ref-type="media"}: Table S1). In total, 67 drugs were excluded because they were rated for topical, nasal, ophthalmic, or otic application only, or were drug combinations (Additional file [1](#MOESM1){ref-type="media"}: Table S2).

In terms of effect, 334 of the drugs were categorised as having no anticholinergic effects (ACB score = 0), 77 of the drugs were scored as displaying weak anticholinergic effects (ACB score = 1), 10 as moderate anticholinergic effects (ACB score = 2) and 27 as strong anticholinergic effects (ACB score = 3). These anticholinergic drugs are displayed in Table [1](#Tab1){ref-type="table"}. Drugs rated as having no anticholinergic effects are available in the supplementary material.Table 1Anticholinergic drugs with concordant ratings of soresDrugATC-CodeCarnahan 2006 USA \[[@CR20]\]Ancelin 2006 France \[[@CR21]\]Rudolph 2008 USA \[[@CR22]\]Han 2008 USA \[[@CR23]\]Ehrt 2010 Norway modified \[[@CR24]\]Sittironnarit 2011 Australia \[[@CR26]\]Boustani 2012 USA \[[@CR40]\]Duran 2013 \[[@CR18]\]Weak anticholinergic effects ACB score 1 AmpicillinJ01CA0110 or 1 AripiprazoleN05AX1201 AtenololC07AB03010010 AzathioprineL04AX0110 or 1 BenazeprilC09AA07010 or 1 BetaxololC07AB05100 or 1 BisacodylA06AB02010 or 1 BromocriptineN04 BC0110weak(1--2) BupropionN06AX120110 or 1 CaptoprilC09AA0110010 or 1 CelecoxibM01AH01010 or 1 ChlordiazepoxideN05BA0211weak(1--2) ChlorthalidoneC03BA041010 or 1 CiclosporinL04 AD0110 or 1 CitalopramN06AB04011weak(1--2) ClindamycinJ01FF0110 or 1 ClonazepamN03AE0111weak(1--2) DexamethasoneH02AB02100 or 1 DextromethorphanR05DA09010 or 1 DiazepamN05BA0111111weak(1--2) DigitoxinC01AA0411weak(1--2) DiltiazemC08DB01100 or 1 DipyridamoleB01AC071010 or 1 DomperidoneA03FA031weak(1--2) EntacaponeN04BX0201weak(1--2) EscitalopramN06AB10010 or 1 FamotidineA02BA03100 or 1 FentanylN02AB0311weak(1--2) FlunitrazepamN05CD0310 or 1 FluoxetineN06AB031111weak(1--2) FlurazepamN05CD0110 or 1 FluvoxamineN06AB081111weak(1--2) GentamicinJ01GB0310 or 1 GuaifenesinR05CA03010 or 1 HydralazineC02DB021010 or 1 HydrocortisoneH02AB09110 or 1 Isosorbide dinitrateC01DA081000 or 1 Isosorbide mononitrateC01DA14100 or 1 KetorolacM01AB151weak(1--2) LansoprazoleA02BC030100 or 1 LevodopaN04BA0101100 or 10 or 1 LithiumN05AN0101weak(1--2) LorazepamN05BA0610 or 1 MetforminA10BA02010 or 1 MethotrexateL04AX03010 or 1 MethylprednisoloneH02AB04100 or 1 MetoprololC07AB02010010 MidazolamN05CD0810 or 1 MirtazapineN06AX1101weak(1--2) MorphineN02AA01111weak(1--2) NaratriptanN02CC0210 or 1 NifedipineC08CA0510010 OxazepamN05BA041010 or 1 OxycodoneN02AA05111weak(1--2) PancuroniumM03 AC0110 or 1 PhenobarbitalN03AA020110 or 1 PiperacillinJ01CA1210 or 1 PramipexoleN04 BC050100 or 1 PrednisoloneA07EA011000 or 1 PrednisoneA07EA0311 QuinidineC01BA0101 RisperidoneN05AX0801111weak(1--2) SelegilineN04BD010100 or 1 SertralineN06AB0611000 SumatriptanN02CC0110 or 1 TemazepamN05CD0711weak(1--2) TrandolaprilC09AA100100 or 1 TrazodoneN06AX050111weak(1--2) TriamcinoloneH02AB08100 or 1 TriamtereneC03DB021010 or 1 TriazolamN05CD0511weak(1--2) Valproic acidN03AG01100 or 1 VancomycinJ01XA0110 or 1 VenlafaxineN06AX16010110 WarfarinB01AA0310010 ZiprasidoneN05AE0410 or 1 ZolmitriptanN02CC0310 or 1Moderate anticholinergic effects ACB score 2 AmantadineN04BB01122weak(1--2) CimetidineA02BA01221weak(1--2) LoperamideA07DA0312111weak(1--2) LoxapineN05AH0122weak(1--2) MethadoneN07 BC022weak(1--2) OxcarbazepineN03AF0222weak(1--2) PimozideN05AG0222weak(1--2) RanitidineA02BA02212111weak(1--2) TheophyllineR03DA0412121weak(1--2) TramadolN02AX02122weak(1--2)Strong anticholinergic effects ACB score 3 AmitriptylineN06AA093333333Strong(3) AtropineA03BA0133333Strong(3) ChlorpheniramineR06AB04333333Strong(3) ClemastineR06AA0433Strong(3) ClomipramineN06AA04333Strong(3) ClozapineN05AH023233Strong(3) CyproheptadineR06AX022332Strong(3) DarifenacinG04BD1033Strong(3) DimenhydrinateA04AB0233Strong(3) DiphenhydramineA04AB053333Strong(3) DoxepinN06AA1233333Strong(3) FlavoxateG04BD0233Strong(3) HydroxyzineN05BB013333Strong(3) ImipramineN06AA02333333Strong(3) LevomepromazineN05AA02232Strong(3) NortriptylineN06AA1032323Strong(3) OrphenadrineN04AB023333Strong(3) OxybutyninG04BD04333323Strong(3) ProcyclidineN04AA043Strong(3) ScopolamineA04AD01333Strong(3) ThioridazineN05 AC0233333Strong(3) TizanidineM03BX023Strong(3) TolterodineG04BD0732333Strong(3) TrihexyphenidylN04AA0133333Strong(3) TrimipramineN06AA063333Strong(3)Drugs are sorted by their assigned score and then alphabetical

Further evaluation was required for 35 drugs. After consideration of adverse drug reactions and mechanism of action, we scored one drug with no anticholinergic effects (ACB score = 0), 22 drugs with weak anticholinergic effects (ACB score = 1), eight as moderate anticholinergic effects (ACB score = 2), and four as having strong anticholinergic effects (ACB score = 3). See Table [2](#Tab2){ref-type="table"} for specific drugs.Table 2Scoring of drugs with discrepant ratings (=ratings differed more than 1 score) or only one previous scoringDrugATC-CodeCarnahan 2006 USA \[[@CR20]\]Ancelin 2006 France \[[@CR21]\]Rudolph 2008 USA \[[@CR22]\]Han 2008 USA \[[@CR23]\]Ehrt 2010 Norway modified \[[@CR24]\]Sittironnarit 2011 Australia \[[@CR26]\]Boustani 2012 USA \[[@CR40]\]Duran 2013 \[[@CR18]\]No anticholinergic effects ACB score 0 ColchicineM04 AC010301discrepantWeak anticholinergic effects ACB score 1 AlprazolamN05BA1213111discrepant AsenapineN05AH051 BaclofenM03BX010221 or 2 CetirizineR06AE07022211 or 2 ClorazepateN05BA05131discrepant CodeineR05DA041210111 or 2 DesloratadineR06AX271 DigoxinC01AA0513111discrepant DoxylamineR06AA0903 FexofenadineR06AX2602201 or 2 FluphenazineN05AB021333 FurosemideC03CA0113101discrepant Ipratropium inhalativeR03BB01033 LevocetirizineR06AE091 LoratadineR06AX13021111 or 2 MethocarbamolM03BA031131 or 2 MetoclopramideA03FA0101301discrepant PaliperidoneN05AX131 PerphenazineN05AB0313203discrepant PromethazineR06AD0233033 PseudoephedrineR01BA02020 oder 1 Tiotropium inhalativeR03BB040Moderate anticholinergic effects ACB score 2 CarbamazepineN03AF01210021 or 2 HaloperidolN05 AD01010211 or 2 MaprotilineN06AA213discrepant PethidineN02AB022021 or 2 OlanzapineN05AH03121231 or 2 OpipramolN06AA053discrepant ParoxetineN06AB051122231 or 2 QuetiapineN05AH04012131 or 2Strong anticholinergic effects ACB score 3 FesoterodineG04BD113 PropiverineG04BD063 SolifenacinG04BD0803 TrospiumG04BD093Drugs are sorted first by their assigned score and then alphabetical

During the retrospective evaluation, 26 drugs were identified that were not yet scored by these already existing scores. Parallel to drugs with inconsistent scores, the adverse drug reactions and the mechanism of action were reviewed and the drugs discussed by three researchers to score the drugs. Five drugs were scored as weak anticholinergic effects (ACB score = 1) and 21 drugs were categorised as having no anticholinergic effects (ACB score = 0). See Table [3](#Tab3){ref-type="table"} for specific drugs.Table 3Drugs added during retrospective evaluationDrugATC-CodeNo anticholinergic effects ACB score 0 AgomelatineN06AX22 ApixabanB01FAF02 ColecalciferolA11CC05 DabigatranB01AE07 DulaglutideA10BJ05 EdoxabanB01AF03 EmpagliflozinA10BK03 Fenoterol inhalativeR03AC04 Formoterol inhalativeR03AC13 MetamizoleN02BB02 Saccharomyces boulardiiA07FA02 PhenprocoumonB01AA04 PipamperoneN05 AD05 PiritramideN02 AC03 RivaroxabanB01AF01 SevelamerV03AE02 SitagliptinA10BH01 TeriparatideH05AA02 ThiamazoleH03BB02 Tilidine/NaloxoneN02AX51 VemurafenibL01XE15Weak anticholinergic effects ACB score 1 Aclidinium inhalativeR03BB05 DimetindeneR06AB03 EtoricoxibM01AH05 Glycopyrronium inhalativeR03BB06 Rotigotine patchN04 BC09Drugs are sorted by their assigned score and then alphabetical

Table [4](#Tab4){ref-type="table"} shows all drugs scored sorted by their score. Additional file [1](#MOESM1){ref-type="media"}: Table S3 shows all drugs scored 0.Table 4Overview of all drugs scored. Caution: This list does not contain necessarily all drugs with anticholinergic propertiesACB score = 1ACB score = 2ACB score = 3Aclidinium^inh^\
Alprazolam\
Ampicillin\
Aripiprazole\
Asenapine\
Atenolol\
Azathioprine\
Baclofen\
Benazepril\
Betaxolol\
Bisacodyl\
Bromocriptine\
Bupropion\
Captopril\
Celecoxib\
Cetirizine\
Chlordiazepoxide\
Chlorthalidone\
Ciclosporin\
Citalopram\
Clindamycin\
Clonazepam\
Clorazepate\
Codeine\
Desloratadine\
Dexamethasone\
Dextromethorphan\
Diazepam\
Digitoxin\
Digoxin\
Diltiazem\
Dimetindene\
Dipyridamole\
Domperidone\
DoxylamineEntacapone\
Escitalopram\
Etoricoxib\
Famotidine\
Fentanyl\
Fexofenadine\
Flunitrazepam\
Fluoxetine\
Fluphenazine\
Flurazepam\
Fluvoxamine\
Furosemide\
Gentamicin\
Glycopyrronium^inh^\
Guaifenesin\
Hydralazine\
Hydrocortisone\
Ipratropium^inh^\
Isosorbide dinitrate\
Isosorbide mononitrate\
Ketorolac\
Lansoprazole\
Levocetirizine\
Levodopa\
Lithium\
Loratadine\
Lorazepam\
Metformin\
Methocarbamol\
Methotrexate\
Methylprednisolone\
Metoclopramide\
Metoprolol\
MidazolamMirtazapine\
Morphine\
Naratriptan\
Nifedipine\
Oxazepam\
Oxycodone\
Paliperidone\
Pancuronium\
Perphenazine\
Phenobarbital\
Piperacillin\
Pramipexole\
Prednisolone\
Prednisone\
Promethazine\
Pseudoephedrine\
Quinidine\
Risperidone\
Rotigotine patch\
Selegiline\
Sertraline\
Sumatriptan\
Temazepam\
Tiotropium^inh^\
Trandolapril\
Trazodone\
Triamcinolone\
Triamterene\
Triazolam\
Valproic acid\
Vancomycin\
Venlafaxine\
Warfarin\
Ziprasidone\
ZolmitriptanAmantadine\
Carbamazepine\
Cimetidine\
Haloperidol\
Loperamide\
Loxapine\
Maprotiline\
Methadone\
Olanzapine\
Opipramol\
Oxcarbazepine\
Paroxetine\
Pethidine\
Pimozide\
Quetiapine\
Ranitidine\
Theophylline\
TramadolAmitriptyline\
Atropine\
Chlorpheniramine\
Clemastine\
Clomipramine\
Clozapine\
Cyproheptadine\
Darifenacin\
Dimenhydrinate\
Diphenhydramine\
Doxepin\
Fesoterodine\
Flavoxate\
Hydroxyzine\
Imipramine\
Levomepromazine\
Nortriptyline\
Orphenadrine\
Oxybutynin\
Procyclidine\
Propiverine\
Scopolamine\
Solifenacin\
Thioridazine\
Tizanidine\
Tolterodine\
Trihexyphenidyl\
Trimipramine\
Trospium^inh^inhalative

Discussion {#Sec4}
==========

To our knowledge, this is the first ACB score developed especially for prescribers in Germany. There have been similar international publications \[[@CR18], [@CR27]\]. The drugs most commonly used in Germany differ from other countries especially England, USA, and Australia, where many published studies on anticholinergic drugs were conducted. Our ACB score did not only summarize existing scores but re-evaluated the drugs, especially those with discrepancies, and reduced the list to those authorized in Germany. This saves valuable time and effort for clinicians trying to evaluate anticholinergic burden in patients.

The scores used were identified via a systematic literature search in pubmed. This systematic approach should ensure a replicable and complete choice of peer-reviewed and published ACB scores, although it was not a systematic literature review conducted in different databases. All included scores were previously validated. Drug evaluation was based on expert opinion which was previously preferred to measuring serum assays \[[@CR18], [@CR27]\]. This expert review of the drugs by three different people (one geriatrician and two clinical pharmacists) based on clinical experience and literature data on method of action and ADRs strengthens the development of this score. Scoring was confirmed by the expert committee not only for drugs with discrepancies, but also for drugs that were only scored by one of the existing scores. Being rated by only one score is not necessarily a limitation as the individual selection of drugs is always depending on the country, the setting, and other specifics of the score development.

As our score is based on previously published ACB scores and drugs within our hospital during a retrospective evaluation, we do not claim this list to be comprehensive. There are over 2000 drugs approved in Germany, so there are potentially more anticholinergic drugs not yet considered in this list. There were few drugs found in our retrospective evaluation that had not been rated by previously published ACB scores. Potential reasons for those drugs missing could be that the drugs were mainly used in Germany and not internationally, e.g. Metamizol sodium, or that the drugs were new on the market and not previously analysed, e.g. Apixaban. To address missing and potentially new anticholinergic drugs, updates are planned in follow-up projects.

The validity of selection of drugs with anticholinergic activity and the grading can be questioned. Among the selected scores there is a great variety in study design and setting. Different methods to assess and rate anticholinergic activity were used: product information, specialised literature on ADRs, review of literature, expert opinion as well as serum radio receptor assay, dissociation constant for cholinergic receptor and other laboratory data \[[@CR10], [@CR18]--[@CR24], [@CR26], [@CR40]\]. We worked with that variety by comparing different scores. As final decision on inclusion and rating of anticholinergic drugs was mainly a subjective decision of experts and not based on clinical outcomes, the ratings may be discussed further. Nevertheless, there is no approved methodology to measure the ACB and expert rating is preferred to measuring serum assays \[[@CR27]\]. The list did not include topical, ophthalmic, otic or nasal drugs. It cannot be excluded that there might be systemic or local anticholinergic effects with these application routes.

The distinction of anticholinergic potency from 0 to 3 might not be the best method to quantify anticholinergic burden, but as most existing scores used this or a similar rating it was the only way to work with the existing lists \[[@CR18], [@CR19]\]. Through the upper limit of score 3, the suggested ceiling effect of the ACB was included \[[@CR19]\]. This means that at a high ACB, drug effects are assumed to reach a plateau even when the number of anticholinergic drugs further increases \[[@CR19]\]. For a more accurate evaluation of anticholinergic burden a finer distinction in some drug classes would be useful. Drug classes like tricyclic antidepressants or anticholinergics for urinary incontinence were all scored with a strong ACB (ACB = 3). Although those drugs all have a strong anticholinergic burden, some are more problematic than others. For example, Trospium should have less central reactions than other anticholinergics for urinary incontinence because of its quaternary chemical structure, but it still shows anticholinergic adverse effects and was rated having strong anticholinergic properties by Boustani et al. \[[@CR40]\]*.* Another method to further refine the evaluation of ACB would be to consider the dosages of anticholinergic drugs via the Drug Burden Index \[[@CR33]\]. A recently published cohort study of German older outpatients found a significant association of the drug Burden Index with Mini-Mental State Examination Score, Barthel index, Falls and use of laxatives \[[@CR42]\]. We did not use this approach as it is more complicated and time-consuming to use in daily routine and it is not compatible with the scores used \[[@CR11]\]. Our decision to apply the higher score (Fig. [2](#Fig2){ref-type="fig"} step 3) might be questioned due to the automatic application of a higher anticholinergic rating. We decided to take this approach in order to avoid missing any drugs with anticholinergic properties.

Although a high anticholinergic burden should be avoided if possible, the deprescribing of anticholinergic drugs is not always possible. Some indications like for example urinary incontinence or some psychiatric indications require anticholinergic medications that cannot be easily subsidised by other non-anticholinergic drugs due to clinical reasons. While urinary incontinence can be handled well with non-pharmacological options, if pharmacological treatment is required anticholinergic drugs are the best options. Thus, this list should be considered as decision support for the prescriber rather than as a strict deprescribing directive.

Conclusion {#Sec5}
==========

Although anticholinergic burden is only one factor of many to consider in multimorbid geriatric patients, it is important to discuss anticholinergic burden and its effects. This list can be used in Germany and countries with similar drugs approved to assess the anticholinergic burden of geriatric patients. It is valuable for prescribers to use in the daily clinical setting as only drugs available in Germany are listed and data from different studies is merged into one table so that a quick overview is possible. Further cluster-randomised studies investigating whether the implementation of the list reduces anticholinergic side effects, falls or delirium are necessary for its validation.

Additional file
===============

 {#Sec6}

Additional file 1:**Table S1.** Drugs extracted from published tools and excluded because they are not available in Germany. NB: This table extends to four pages. **Table S2.** Drugs extracted from published tools and excluded because they are topical, nasal, ophthalmic, or otic drugs or drug combinations. NB: This table extends to two pages. **Table S3.** All drugs scored 0. NB: This table extends to eight pages. (DOCX 157 kb)

ACB

:   Anticholinergic burden

ADR

:   Adverse drug reaction

ATC

:   Anatomical, Therapeutic and Chemical
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